Copyright
©The Author(s) 2021.
World J Cardiol. Aug 26, 2021; 13(8): 271-297
Published online Aug 26, 2021. doi: 10.4330/wjc.v13.i8.271
Published online Aug 26, 2021. doi: 10.4330/wjc.v13.i8.271
| Type of pathology | Pathology |
| Cardiomyopathies | HCM |
| DCM | |
| LVNC | |
| ARVC | |
| CAD | |
| Myocarditis | |
| Congenital defects | AOCA |
| BAV | |
| Valvulopathies | MVP |
| Aortic diseases | Aortic dissection |
| Aortic rupture | |
| Aortic aneurism | |
| Kawasaki disease | |
| Idiopathic scarring | |
| Conduction defects | WPW |
| Channelopathies | LQTs |
| Brugada syndrome | |
| CPVT | |
Table 2 Minimum dataset for transthoracic echocardiography (adapted from[33])
| Echo views | Structure | Measure |
| PLAX | LV | IVS |
| End diastolic diameter | ||
| Posterior wall | ||
| Wall motion | ||
| Mitral Valve | Leaflets and annulus | |
| Color | ||
| Aortic Valve | Anulus | |
| Valsalva Sinus | ||
| STJ | ||
| Color | ||
| Ascending aorta | Size | |
| RV | RVOT | |
| LA | Size | |
| PSAX–aortic valve | Aortic Valve | Morphology |
| OCA | ||
| RV | RVOT | |
| Pulmonary valve | Color | |
| PW | ||
| PSAX-base | Mitral Valve | Leaflets and annulus |
| PSAX–mid/apex | LV | Wall motion |
| A4C | LV | EF |
| Wall motion | ||
| Wall thickness | ||
| End diastolic area/volume | ||
| VSD | ||
| ASD | ||
| LA | LAVI | |
| Mitral valve | Color | |
| PW | ||
| TDI | ||
| RV | RVD1 | |
| RVD2 | ||
| RVD3 | ||
| Wall motion | ||
| TAPSE | ||
| TV | Color | |
| CW | ||
| Pulmonary veins | PW | |
| A5C | Aortic valve | Color |
| CW | ||
| A2C | LV | Wall motion |
| Subcostal | ASD | |
| Inferior vena cava | Size | |
| Breath collapsibility | ||
| Pericardium | Pericardial effusion | |
| Abdominal aorta | Size | |
| Suprasternal | Aortic arch | Size |
| Color | ||
| CW |
Table 3 Athlete-focused echo protocols
| Ref. | Echo view (parameters assessed) | Estimated exam time |
| Feinstein et al[51] | PLAX (LV IVS, LV posterior wall, LVOT) | 1-2 min |
| Wyman et al[53] | PLAX (aortic arch size, aortic valve characteristics, mitral valve characteristics, LV wall motion, LV mass); PSAX (aortic valve characteristics, aortic valve morphology, origin of coronary arteries, CW pulmonary valve, LV wall motion, LV wall thickness); A4C (tricuspid valve characteristics, mitral valve characteristics, RV size, RV wall motion, LV size); A5C (CW aortic valve) | Not specified |
| Weiner et al[52] | PLAX (aortic valve characteristics, mitral valve characteristics, CW tricuspid valve); PSAX (aortic valve characteristics, pulmonary valve characteristics, LV wall motion); A4C (RV size, RV wall motion, LV size, LV wall motion, PW mitral valve, TDI mitral valve, tricuspid valve characteristics); A5C (CW aortic valve); A2C (LV wall motion) | 13 min |
| Yim et al[55] | PLAX (IVS, LV end diastolic diameter, PW, aortic arch size) | Not specified |
| Fishman et al[54] | LV IVS, LV posterior wall, LV end diastolic diameter, PW, EF, AVR, MVR aortic valve regurgitation, mitral valve regurgitation, aortic valve morphology, aortic root dimension | 1 min |
Table 4 Proposed echocardiographic protocol for athletes
| Echo views | Structure | Measure |
| PLAX | LV | IVS |
| End diastolic diameter | ||
| Posterior wall | ||
| Mitral valve | Leaflets | |
| Color | ||
| Aortic valve | Valsalva sinus | |
| Color | ||
| Ascending aorta | Size | |
| PSAX–aortic valve | Aortic valve | Morphology |
| OCA | ||
| RV | RVOT | |
| PDA | ||
| A4C | LV | Trabeculations |
| Wall motion | ||
| VSD | ||
| ASD | ||
| Mitral valve | Color | |
| PW | ||
| TV | Color | |
| CW | ||
| A5C | Aortic valve | Color |
| CW | ||
| Subcostal | ASD | |
| Inferior vena cava | Size | |
| Breath collapsibility | ||
| Pericardium | Pericardial effusion | |
| Suprasternal | Aortic arch | Size |
| COA |
Table 5 Main echo findings of cardiovascular pathologies in athletes
| Pathology | What to assess? (echo view) | Cut-off mm (mean mm) | If pathological, what to assess? (echo view) | Cut-off mm (mean mm) |
| HCM | LV Max end-diastolic wall thickness | M white 15 (10); M Afro-American 16 (11.5); F white 11; F Afro-American 13 (9.5); M/F adolescent 16 (12) | LV wall thickness distribution | Asymmetric (HCM) |
| LV end diastolic diameter (A4C) | M 70 (55); F 66 (49); Adolescent 60 (51) | |||
| LV mass/BSA | M 117 mm/m2 (83 mm/m2); F 143 mm/m2 (101 mm/m2) | |||
| LVOT obstruction | ||||
| E/A (A4C) | 1.3 (1.93) | |||
| DCM | LV end diastolic diameter (PLAX) | M 70 (50); F 66 (49); Adolescent 60 (51) | EF (A4C) | 55% (64%) |
| LVNC | LV trabeculation | NC/C layer ratio > 2.0 in systole | EF (A4C) | 55% (64%) |
| Thickness of compact layer in systole | 8 | |||
| E/A (A4C) | 1.3 (1.93) | |||
| ARVC | RVOT/BSA (PSAX) | > 21 mm/m2 | RV inflow (A4C)/ LV end diastolic diameter (PLAX) | > 0.9 |
| RVOVT/BSA (PLAX) | > 19 mm/m2 | RV wall motion abnormalities | ||
| RV FAC | 33% | |||
| Aortic dilatation | Aortic valve max dimension (PLAX) | M 40 (32); F 34 (28) | Other congenital defects (BAV) | |
| Ascending aorta dimension (PLAX) | Aortic regurgitation | |||
| Mitral prolapse | Mitral prolapse (PLAX) | Abnormal systolic bulging of leaflets > 2 mm toward LA | Mitral regurgitation | |
| PAPS (A4C) | 40 mmHg (24 mmHg) | |||
| Pulmonary veins flow | Reverse | |||
| EF (A4C) | 55% (64%) | |||
| LV mass/BSA | M 117 mm/m2 (83 mm/m2); F 143 mm/m2 (101 mm/m2) | |||
| LAVI | M 36 mm/m2 (28 mm/m2); F 33 mm/m2 (26.5 mm/m2) | |||
| AOCA | Coronary arteries origin (PSAX) | |||
| BAV | Aortic morphology (PSAX) | Aortic stenosis | ||
| Aortic regurgitation | ||||
| Aortic root max dimension (PLAX) | M 40 (32); F 34 (28) | |||
| Other congenital defects (coarctation of the aorta, interrupted aortic arch, patent ductus arteriosus, coronary anomaly or hypoplastic left heart, as well as Williams or Turner syndrome) | ||||
| ASD | ASD | RV dimension (A4C) | Basal RV: M 55 (43.5), F 49 (39); Medial RV: M 47 (34), F 43 (32); Longitudinal RV: M 109 (89), F 100 (82) | |
| RA area/BSA (A4C) | M 28 mm/m2 (19.5 mm/m2); F 24 mm/m2 (15.5 mm/m2) | |||
| PAPS (A4C) | 40 mmHg (24 mmHg) | |||
| VSD | VSD | LV mass/BSA (PLAX) | M 117 mm/m2 (83 mm/m2); F 143 mm/m2 (101 mm/m2) | |
| PAPS (A4C) | 40 mmHg (24 mmHg) | |||
| Aortic regurgitation | ||||
| Other congenital defects (aneurysm of Valsalva sinus, ToF, TGA, DCRV) | ||||
| PDA | PDA (PSAX) | LA/Aortic root ratio | ≥ 1.4 | |
| LV mass/BSA (PLAX) | M 117 mm/m2 (83 mm/m2); F 143 mm/m2 (101 mm/m2) | |||
| PAPS (A4C) | 40 mmHg (24 mmHg) | |||
| Pulmonary artery size (PSAX) | ||||
| RV dimension (A4C) | Basal RV: M 55 (43.5), F 49 (39); Medial RV: M 47 (34), F 43 (32); Longitudinal RV: M 109 (89), F 100 (82) | |||
| RA area/BSA (A4C) | M 28 mm/m2 (19.5 mm/m2); F 24 mm/m2 (15.5 mm/m2) | |||
| Other congenital defects (COA, pulmonary atresia) | ||||
| COA | COA (PSAX) | Aortic stenosis | ||
| Mitral stenosis | ||||
| LV mass/BSA (PSAX) | M 117 mm/m2 (83 mm/m2); F 143 mm/m2 (101 mm/m2) | |||
| EF (A4C) | 55% (64%) | |||
| Other congenital defects (BAV, ascending aortic aneurysm) | ||||
| Myocarditis | EF (A4C) | 55% (64%) | ||
| LV wall motion abnormalities | ||||
| Pericardial effusion | ||||
| Increased LV wall thickness | ||||
| Pericarditis | Pericardial effusion | |||
| Kawasaki disease | Coronary artery abnormalities | |||
| EF (A4C) | 55% (64%) | |||
| LV wall motion abnormalities | ||||
| Mitral regurgitation | ||||
| Aortic regurgitation | ||||
| Pericardial effusion | ||||
Table 6 Differential diagnosis between hypertrophic cardiomyopathy and athlete’s heart, in the grey-zone (adapted from[42])
| HCM | Findings | Athlete’s heart |
| Normal, reduced | LV cavity size | Enlarged, eccentric pattern |
| Asymmetric and heterogeneous | LV hypertrophy | Symmetric and homogeneous |
| Present | LVOT obstruction | Absent |
| Abnormal | LV diastolic function | Normal |
| Unchanged | LV wall thickness after detraining | Reduced |
Table 7 Differential diagnosis between dilated cardiomyopathy and athlete’s heart (adapted from[42])
| DCM | Findings | Athlete’s heart |
| > 60 mm | LV end diastolic diameter | < 60 mm |
| Reduced | EF | Normal |
| Abnormal | Diastolic function | Normal |
Table 8 Differential diagnosis between left ventricle non compaction and athlete’s heart, in the grey zone (adapted from[42])
| LVNC | Findings | Athlete’s heart |
| Reduced | LV systolic function | Normal |
| Reduced | Thickness of compact layer | Normal |
| Abnormal | Diastolic function | Normal |
Table 9 Differential diagnosis between arrhythmogenic right ventricular cardiomyopathy and athlete’s heart, in the grey-zone (adapted from[42])
| ARVC | Findings | Athlete’s heart |
| Exceeding major criteria for ARVC | RV size | Not exceeding major criteria for ARVC |
| Abnormal | Regional RV wall motion | Normal |
| Abnormal | Global RV function | Normal |
Table 10 Echocardiographic criteria for the definition of severe valve regurgitation (adapted from[165])
| AVR | MVR | TVR | |
| Vena contracta width (mm) | > 6 | ≥ 7 | ≥ 7 |
| Other | Pressure half-time < 200 ms | TVI mitral/TVI aortic > 1.4 | PISA radius > 9 mm |
| EROA (mm2) | ≥ 30 | ≥ 40 | ≥ 40 |
| Regurgitant volume (mL/beat) | ≥ 60 | ≥ 60 | ≥ 45 |
| AVS | MVS | TVS | PVS | |||||||
| Low | Moderate | Severe | Low | Moderate | Severe | Clinically significant | Low | Moderate | Severe | |
| V max (m/s) | 2.6-2.9 | 3.0-3.4 | ≥ 4.0 | < 3 | 3-4 | ≥ 4 | ||||
| DP mean (mmHg) | < 30 | 30-40 | ≥ 40 | < 5 | 5-10 | > 10 | > 5 | < 30 | 30-50 | > 50 |
| Valve orifice area (cm2) | > 1.5 | 1.0-1.5 | < 1.0 | > 1.5 | 1.0-1.5 | < 1.0 | ||||
- Citation: Palermi S, Serio A, Vecchiato M, Sirico F, Gambardella F, Ricci F, Iodice F, Radmilovic J, Russo V, D'Andrea A. Potential role of an athlete-focused echocardiogram in sports eligibility. World J Cardiol 2021; 13(8): 271-297
- URL: https://www.wjgnet.com/1949-8462/full/v13/i8/271.htm
- DOI: https://dx.doi.org/10.4330/wjc.v13.i8.271
